This video explains why, due to decreasing antibody levels, and the rise of new variants, the COVID-19 booster is necessary. The video also compares hospitalization and mortality rates between vaccinated and unvaccinated individuals to highlight the efficacy of the vaccine at reducing severe disease outcomes.
This video was made by McMaster students Anusha Desai, Abdalmuhaymen Ibrahim, Hasan Salman, and Samara Hasan in collaboration with the McMaster Demystifying Medicine Program.
Subscribe to the McMaster Demystifying Medicine YouTube channel: [ Ссылка ]
This video is provided for general and educational information only. Please consult your health care provider for Information about your health.
Copyright McMaster University 2022
References
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years—PubMed. (n.d.). Retrieved 4 February 2022, from [ Ссылка ]
Canada, P. H. A. of. (2020, April 19). COVID-19 daily epidemiology update [Datasets;statistics;education and awareness]. Aem. [ Ссылка ]
Confirmed Cases of COVID-19 Following Vaccination in Ontario: December 14, 2020 to January 30, 2022. (n.d.). 22.
Confirmed Cases of COVID-19 Following Vaccination .pdf. (n.d.). Retrieved 4 February 2022, from [ Ссылка ]
Coon, L. (2021, October 25). What is a booster shot and why do I need it? | OSF HealthCare. OSF HealthCare Blog. [ Ссылка ]
Coronavirus (COVID-19): What Are Booster Shots? (For Parents)—Nemours KidsHealth. (n.d.). Retrieved 4 February 2022, from [ Ссылка ]
COVID Natural Immunity: What You Need to Know | Johns Hopkins Medicine. (n.d.). Retrieved 4 February 2022, from [ Ссылка ]
COVID-19 vaccinations data. (n.d.). COVID-19 (Coronavirus) in Ontario. Retrieved 4 February 2022, from [ Ссылка ]
Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A. P., Maruste, R., Kärner, J., Gerhold, J. M., Planken, A., Ustav, M., Kisand, K., & Peterson, P. (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. The Lancet Regional Health – Europe, 10. [ Ссылка ]
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel | NEJM. (n.d.). Retrieved 4 February 2022, from [ Ссылка ]
Ritchie, H., Mathieu, E., Rodés-Guirao, L., Appel, C., Giattino, C., Ortiz-Ospina, E., Hasell, J., Macdonald, B., Beltekian, D., & Roser, M. (2020). Coronavirus Pandemic (COVID-19). Our World in Data. [ Ссылка ]
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021).
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309), 1407–1416. [ Ссылка ]02183-8
Yue, L., Xie, T., Yang, T., Zhou, J., Chen, H., Zhu, H., Li, H., Xiang, H., Wang, J., Yang, H., Zhao, H., Wei, X., Zhang, Y., & Xie, Z. (2022). A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine. Journal of Medical Virology, 94(1), 35–38. [ Ссылка ]
